glp-1 news today october 2025 Weight-Loss Drug Demonstration Begins July 2026 Oral - Glp-1 receptor agonist

The European Medicines Agency recommends evaluating treatment response at 12 weeks and continuing only if the patient achieves at least 5% body weight reduction

doi: 10.2337/dc19-0749

Williams, who retired from professional tennis in 2022, told PORTER magazine: "It was hard because when I was playing in the beginning the first 15 years my body was different

Weight loss medications may make you lose your appetite and cravings for food, but they wont touch the underlying root causes of why you turned to food to soothe

How insurance companies set their own BMI cutoffs for GLP-1 coverage Here is where the conversation gets complicated

Marsha Novick: Mild nausea, constipation, diarrhea, fatigue, and low appetite are fairly common with GLP-1 medications like semaglutide (Wegovy) and tirzepatide (Zepbound), especially in the first few days after an injection or after a dose increase